Should We Be Screening for SARS-CoV-2 in IBD Patients Before Initiation of Biologic Therapy?

Inflamm Bowel Dis. 2021 Jan 19;27(2):291-294. doi: 10.1093/ibd/izaa173.

Authors

Jana G Hashash¹, Suha Jabak¹, Fadi F Francis¹, Miguel Regueiro²

Affiliations

¹ Division of Gastroenterology, American University of Beirut, Lebanon.
² Division of Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic, OH, USA.

No abstract available

Keywords: COVID-19; IBD; SARS-CoV-2; biological therapy.

Publication types

Editorial

MeSH terms

Biological Therapy / adverse effects*
COVID-19 / chemically induced
COVID-19 / diagnosis*
COVID-19 Testing / methods*
Humans
Inflammatory Bowel Diseases / drug therapy*
Inflammatory Bowel Diseases / virology
SARS-CoV-2*